AB2 Bio Ltd.
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs. Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 mutation and XIAP deficiency (primary HLH), Macrophage Activation Syndrome (secondary HLH), Adult onset Still`s Disease and others. AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases. Extensive Phase I, Ib and II clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in primary HLH: NLRC4 mutation and XIAP deficiency and in Adult onset Still’s Disease.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info: